NCT02721043View on ClinicalTrials.gov

Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

November 12, 2019

Study Completion Date

June 8, 2020

Conditions
Solid Tumors
Interventions
BIOLOGICAL

Peptides

Each subject will receive ten (10) total doses of PGV001. PGV001 will be administered on study visit: v4, v6, v8, v10, v12, v14, v16, v18, v20 and v22.

DRUG

Poly-ICLC

Each subject will receive ten additional (10) total doses of the Poly-ICLC. The additional Poly-ICLC dose will be administered on study visit: v5, v7, v9, v11, v13, v15, v17, v19, v21 and v23.

DRUG

Lenalidomide

10mg once daily oral dose for maintenance therapy in multiple myeloma patients.

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
lead

Nina Bhardwaj

OTHER

NCT02721043 - Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies | Biotech Hunter | Biotech Hunter